Browse the evidence

High dietary protein intake is not detrimental to bone health and may support bone microarchitecture and strength, particularly from animal and dairy sources.

You do not need to limit protein for the sake of your bones. High protein intake, especially from dairy and animal sources, is associated with stronger bone structure. Ensure adequate calcium and vitamin D, but do not fear protein.

Hormonal contraceptive (HC) use is associated with a lower likelihood of experiencing menstrual cycle symptoms, specifically uterine cramps, in resistance-trained athletes.

If you are a resistance-trained athlete experiencing severe menstrual cramps, hormonal contraceptives (particularly combined oral pills) are statistically associated with a reduction in these symptoms. However, be aware that nearly half of users report unwanted side effects from the contraceptives themselves. Consult a healthcare provider to weigh the benefit of reduced cramping against the risk of HC side effects.

Competitive-level resistance-trained athletes are significantly less likely to alter their training load or volume due to menstrual cycle symptoms compared to recreational athletes.

If you are a competitive strength athlete, you are statistically less likely to skip or reduce training due to menstrual symptoms than a recreational lifter. This is likely due to competitive drive. However, be aware that 69.5% of all participants still altered their programs, so monitor your fatigue and load to ensure you are not compromising long-term recovery or health.

Increased physical activity during GLP-1 RA therapy may help attenuate the medication-associated increase in resting heart rate, though this effect was not statistically significant in this study.

If you are experiencing an increased heart rate on GLP-1 medication, try to incorporate more physical activity. This study suggests that higher activity levels might help blunt this increase, although more research is needed to confirm this. Aim for any amount of movement, as even small increases (median split was <10 min/day) showed a trend toward benefit.

Pregnant women face significant modifiable barriers to physical activity, primarily intrapersonal factors (time constraints, fatigue, lack of motivation) and interpersonal factors (lack of healthcare provider advice), which can be addressed through targeted education and counseling.

Pregnant women in resource-limited settings should be counseled by healthcare providers on the safety and benefits of physical activity, specifically highlighting that walking and household chores count as exercise. Addressing fatigue through light activity and providing clear guidelines can overcome common barriers like lack of time and motivation.

Possession of the GLI3 rs10263647 T/T genotype prevents resistance training-induced increases in vastus lateralis muscle fiber cross-sectional area (fCSA), whereas T/C and C/C genotypes exhibit significant hypertrophy.

If you are a young man starting resistance training, your genetics (specifically the GLI3 gene) may dictate whether your muscle fibers actually increase in size. Those with the T/T genotype may not see muscle fiber growth despite training, while those with T/C or C/C genotypes will likely see significant growth. This is a biological filter, not a failure of effort.

The GLI3 rs10263647 T/T genotype is associated with a failure to increase satellite cell numbers and a failure to add myonuclei in response to resistance training, unlike T/C and C/C genotypes.

For young men with the GLI3 T/T genotype, resistance training may not trigger the cellular machinery (satellite cell addition and myonuclear accretion) typically required for muscle growth. This explains why some individuals do not see muscle fiber enlargement despite consistent effort.

Probiotic supplementation has a regulatory effect on weight and BMI, with greater weight loss magnitude observed in populations with longer treatment durations.

If you are considering probiotics for weight management, look for strains with clinical evidence for obesity. The paper notes that longer treatment durations are associated with greater weight loss, suggesting consistency is key. It is not a quick fix but may support metabolic health over time.

Lifestyle interventions (diet and exercise) significantly improve sperm normal morphology and progressive motility in men with obesity, whereas bariatric surgery and pharmacotherapy (metformin/liraglutide) show no clinically significant improvements in semen parameters or DNA damage.

If you are overweight and trying to conceive, focus on sustainable lifestyle changes (diet and exercise) rather than seeking surgical or pharmacological weight loss solutions solely for fertility. Lifestyle changes have been shown to improve sperm morphology and motility, whereas surgery and weight-loss drugs have not shown consistent benefits for semen quality in this population.

Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.

Your genes can affect how well tirzepatide works for you. If you have certain genetic variants, you might need a different dose or might experience different side effects. Talk to your doctor about genetic testing to personalize your treatment.

Pre-pregnancy lifestyle interventions (dietary restriction or exercise) initiated at least 9 weeks prior to conception reduce the risk of metabolic-associated fatty liver disease (MAFLD) in offspring of obese mothers, whereas interventions initiated only 1 week prior do not.

If you have obesity and plan to conceive, starting weight management 9+ weeks before trying to get pregnant is critical for your future child's liver health. Standard lifestyle changes may take too long, so discuss pre-pregnancy pharmacotherapy (like GLP-1 agonists) with your doctor to ensure you reach a healthy weight before conception.

Pre-pregnancy use of GLP-1 receptor agonists (e.g., liraglutide) or GLP-1/GIP co-agonists (e.g., tirzepatide) is a promising pharmacotherapeutic strategy for pre-pregnancy weight loss in obese women, potentially mitigating the intergenerational risk of MAFLD in offspring, provided sufficient wash-out periods are observed.

If lifestyle changes aren't enough to help you reach a healthy weight before pregnancy, talk to your doctor about GLP-1 medications. They are effective for weight loss and may improve your future child's liver health. Crucially, you must stop these medications well before trying to conceive to ensure they are out of your system.

Among Japanese patients with type 2 diabetes, low intake of vegetables (specifically green-yellow and other vegetables) and high intake of sweets are the strongest dietary predictors of obesity, with these associations holding true across both men and women.

For Japanese patients with Type 2 Diabetes, managing obesity relies less on counting total calories and more on food quality. Prioritize increasing intake of green-yellow and other vegetables, as low vegetable intake is a strong predictor of obesity. Simultaneously, reduce sweets. If you consume sweets, ensure you are also eating a median amount of fruit, which may mitigate the obesity risk, but do not exceed median sweets intake even with high fruit consumption.

Combining low intake of total vegetables with low intake of fruits creates a synergistic effect that significantly increases the odds of obesity, with the highest risk observed when both are in the lowest quartiles.

Do not skip fruits. The highest risk for obesity occurs when you eat very few vegetables AND very few fruits. Eating both in adequate amounts (top quartiles) offers the strongest protection against obesity.

N-of-1 study designs provide a higher level of evidence for determining individualized treatment efficacy in medical nutrition therapy compared to traditional Randomized Controlled Trials (RCTs), which often mask individual variance through mean effect sizes.

If you are a dietitian, standard RCT-based guidelines may not work for every patient because individual responses vary widely. To practice true precision nutrition, consider using N-of-1 trial designs (testing one patient against themselves with multiple diet phases) to identify the specific dietary pattern that works for that individual's biology and lifestyle, rather than relying solely on population averages.

Low-load resistance training (50% 1RM) produces greater acute muscle swelling (cellular hydration) than high-load resistance training (85% 1RM) when volume load is equated, primarily due to increased time under tension and training density.

If your goal is to maximize the 'pump' (acute muscle swelling) in a single workout, use lighter weights (around 50% of your max) and perform more reps until you can't do another one. This creates more time under tension and metabolic stress than heavy lifting, which may support muscle growth mechanisms, even though the total weight moved is the same.

A 14-day continuous adaptive infusion of the GLP-1/GCGR co-agonist G3215 produces significant weight loss (mean -2.39 kg) and reduced food intake in adults with overweight or obesity, with adverse effects mitigated by real-time dose adjustment.

This study shows that a 14-day continuous infusion of a specific hormone drug (G3215) can lead to about 2.4 kg of weight loss in adults with overweight or obesity. The drug works by reducing food intake and increasing energy expenditure. Side effects like nausea were common but manageable by adjusting the infusion rate. This approach might offer faster weight loss with better tolerability than current weekly injection options, though it requires wearing a pump for two weeks.

GLP-1 receptor agonists (e.g., semaglutide/Ozempic) suppress appetite and hunger signals by mimicking the hormone GLP-1, leading to significant weight loss but also causing a loss of the sensory and relational pleasure of eating.

GLP-1 drugs like semaglutide work by mimicking a hormone to reduce hunger and increase fullness, leading to weight loss. However, this comes with side effects like nausea and a reduced ability to enjoy food. The paper highlights that while these drugs can help with weight loss, they do not guarantee mental health improvements or self-acceptance, and weight regain is common if treatment stops. They are expensive and often used off-label.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce modest weight loss (2.3–5%) in breast cancer patients, which is significantly attenuated compared to non-cancer populations, likely due to concurrent endocrine therapy.

If you have breast cancer and are taking hormone-blocking therapy, GLP-1 drugs like semaglutide will likely help you lose some weight, but not as much as they do for people without cancer. Expect a modest loss (around 2-5%) rather than dramatic results. This is likely because your cancer treatment changes your metabolism. It appears safe regarding cancer recurrence, but discuss timing with your oncologist.

GLP-1 receptor agonist use in breast cancer patients does not increase the risk of cancer recurrence and may reduce cardiovascular morbidity.

For breast cancer patients, GLP-1 drugs appear safe regarding cancer recurrence. They may also offer significant cardiovascular protection, which is valuable since some cancer treatments can stress the heart. This benefit exists independently of weight loss.

Sympathomimetic agents (phentermine, phentermine/topiramate, naltrexone/bupropion) cause mild gastrointestinal side effects (constipation, dry mouth, nausea) with lower discontinuation rates compared to GLP-1 agonists.

If you take a sympathomimetic medication like phentermine or naltrexone/bupropion, you may experience mild side effects like constipation or dry mouth. These are generally less severe than the GI side effects associated with GLP-1 agonists. Stay hydrated and monitor your symptoms.

Health and well-being coaching (HWC) serves as an effective adjuvant intervention to GLP-1 receptor agonists by improving medication adherence and promoting sustainable lifestyle changes, thereby mitigating the high rates of weight regain and discontinuation associated with GLP-1 monotherapy.

If you are using a GLP-1 medication like Ozempic or Wegovy, do not rely on it alone. Engage a health coach to help you build sustainable habits around diet and exercise. This support is crucial for sticking with the medication, managing side effects, and ensuring you keep the weight off long-term, especially if you plan to stop the drug eventually.

Weight loss, particularly through GLP-1 based pharmacotherapy (e.g., Tirzepatide), significantly reduces OSA severity and improves cardiometabolic markers like blood pressure, offering a promising alternative or adjunct to CPAP.

Losing weight is one of the most effective ways to treat OSA. New medications like Tirzepatide are showing great promise in reducing breathing pauses and improving blood pressure in obese patients. However, access and cost remain significant barriers.

Combining tirzepatide with low-energy ketogenic therapy (LEKT) produces significantly greater reductions in hepatic steatosis and liver stiffness than combining tirzepatide with a low-calorie diet (LCD), independent of total body weight loss.

If you have MASLD and are using tirzepatide, adding a structured low-energy ketogenic diet (under 30g carbs, ~1200 kcal) for 12 weeks may reduce liver fat and stiffness more effectively than a standard low-calorie diet, even if your total weight loss is similar. This requires strict adherence and monitoring, ideally under medical supervision, to ensure safety and efficacy.